Federal Register / Vol. 87, No. 53 / Friday, March 18, 2022 / Notices 15441 

Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request a copy of the clearance requests 

submitted to OMB for review, email 

Samantha Miller, the acting HRSA 

Information Collection Clearance Officer 

at paperwork@hrsa.gov or call (301) 

443–9094. 

SUPPLEMENTARY INFORMATION: 

Information Collection Request Title: 

Rural Health Clinic COVID–19 (RHC 

COVID–19) Reporting Portal, OMB No. 

0906–0056—Revision. 

Abstract: In October 2020, HRSA’s 

Federal Office of Rural Health Policy 

(FORHP) created a monthly, aggregate 

data report to collect information on 

COVID–19 testing and related expenses 

conducted by funded organizations 

participating in the RHC COVID–19 

Testing (RHCCT) Program funded 

through the Paycheck Protection 

Program and Health Care Enhancement 

Act (Pub. L. 116–139). FORHP is 

expanding this data report to collect 

information on COVID–19 testing, 

COVID–19 mitigation, and related 

expenses conducted by funded 

organizations participating in the RHC 

COVID–19 Testing and Mitigation 

(RHCCTM) Program funded through the 

American Rescue Plan Act (Pub. L. 117– 

2). Funded organizations were 

identified by Tax Identification Number 

(TIN), and a TIN organization may 

operate one or more RHC sites which 

were identified by unique CMS 

Certification Numbers. Respondents are 

TIN organizations who received funding 

for COVID–19 testing, COVID–19 

mitigation, and related expenses. HRSA 

issued RHCCTM funding as one-time 

payments to 2,301 TIN organizations 

based on the number of certified RHC 

sites they operate, providing $100,000 

per clinic site (4,459 RHC sites total 

across the country). Data report 

information is needed to comply with 

federal requirements to monitor funds 

distributed under the Paycheck 

Protection Program and Health Care 

Enhancement Act and the American 

Rescue Plan Act. 

A 60-day notice published in the 

Federal Register, 87 FR 103 (January 3, 

2022). There were no public comments. 

Need and Proposed Use of the 

Information: The RHC COVID–19 

Reporting Portal collects information 

from RHC-funded providers who use 

RHCCT Program funding and RHCCTM 

Program funding to support COVID–19 

testing, expand access to testing in rural 

communities, and other related 

expenses. The RHC COVID–19 

Reporting Portal also collects 

information from RHC-funded providers 

who use RHCCTM Program funding to 

support COVID–19 mitigation and other 

related expenses. These data are critical 

to meet FORHP’s requirements to 

monitor and report on how federal 

funding is being used and to measure 

the effectiveness of the RHCCT Program 

and RHCCTM Program. Revisions 

include a confirmation page for TIN 

organization self-certification following 

completion of each program after the 

period of availability. Specifically, these 

data will be used to assess the 

following: 

• Whether program funds are being 

spent for their intended purposes; 

• COVID–19 testing or testing related 

use(s) of RHCCTM funds; 

• COVID–19 mitigation or mitigation 

related use(s) of RHCCTM funds; 

• Where COVID–19 testing supported 

by these funds is occurring; 

• Number of at-home (i.e., home 

collection; direct-to-consumer; over-thecounter) COVID–19 tests distributed 

(optional); 

• Number of COVID–19 tests; 

• Number of positive COVID–19 tests; 

• TIN organizations self-certification 

of complete expenditure of RHCCT 

Program funds and/or full or partial 

return of RHCCT Program funds; and 

• TIN organizations self-certification 

of complete expenditure of RHCCTM 

Program funds and/or full or partial 

return of RHCCTM Program funds. 

Likely Respondents: Respondents are 

TIN organizations who own or operate 

one or more RHC who received funding 

for COVID–19 testing, COVID–19 

mitigation, and related expenses. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

RHC COVID–19 Reporting Portal ....................................... 2,301 19 43,719 0.33 14,427 

Total .............................................................................. 2,301 ........................ 43,719 ........................ 14,427 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2022–05719 Filed 3–17–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 


jspears on DSK121TN23PROD with NOTICES1
15442 Federal Register / Vol. 87, No. 53 / Friday, March 18, 2022 / Notices 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Clinical Trials and 

Biomarker Studies in Stroke. 

Date: April 11, 2022. 

Time: 8:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Boulevard, 

Suite 3208, MSC 9529, Bethesda, MD 20892, 

301–435–6033, rajarams@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: March 15, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05775 Filed 3–17–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Time-Sensitive 

Obesity PAR review. 

Date: April 19, 2022. 

Time: 11:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NIDDK/National Institutes of Health, 

6707 Democracy Blvd., Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Michele L. Barnard, Ph.D., 

Scientific Review Officer, Review Branch, 

Division of Extramural Activities, NIDDK, 

National Institutes of Health, Room 7353, 

6707 Democracy Boulevard, Bethesda, MD 

20892–2542, (301) 594–8898, barnardm@

extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: March 15, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05772 Filed 3–17–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel; Exploratory/Developmental 

Research Grant Program Review Panel. 

Date: April 8, 2022. 

Time: 2:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700B Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Ranga Srinivas, Ph.D., 

Chief, Extramural Project Review Branch, 

National Institute on Alcohol Abuse and 

Alcoholism, National Institutes of Health, 

6700 B Rockledge Drive, Room 2114, 

Bethesda, MD 20892, (301) 451–2067, 

srinivar@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards, National 

Institutes of Health, HHS) 

Dated: March 14, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05726 Filed 3–17–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Deciphering Immune-CNS Interactions in 

HIV (R01, R21). 

Date: April 14, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Rebecca Steiner Garcia, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Room 6149, MSC 9608, Bethesda, MD 20892– 

9608, 301–443–4525, steinerr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 


jspears on DSK121TN23PROD with NOTICES1